Differential effect of sucrose and fructose in combination with a high fat diet on intestinal microbiota and kidney oxidative stress

Nutrients

Volumn 9, Issue 4, 2017, Pages

  Rosas Villegas, Adriana ^a   Sánchez Tapia, Mónica ^a   Avila Nava, Azalia ^a   Ramírez, Victoria ^a   Tovar, Armando R ^a   Torres, Nimbe ^a  

^a INSTITUTO NACIONAL DE CIENCIAS MÉDICAS Y NUTRICIÓN SALVADOR ZUBIRÁN   (Mexico)

Author keywords

Fructose; Inflammation; LPS; Microbiota; Obesity; Renal oxidative stress; Sucrose

Indexed keywords

FRUCTOSE; INSULIN; LIPOPOLYSACCHARIDE; LOW DENSITY LIPOPROTEIN; MALONALDEHYDE; STEROL REGULATORY ELEMENT BINDING PROTEIN 1; SUCROSE; NUTRITIVE SWEETENER;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DNA SEQUENCE; ELECTROPHORESIS; ENERGY EXPENDITURE; GENE EXPRESSION; GLUCOSE BLOOD LEVEL; GLUCOSE INTOLERANCE; GLUCOSE TOLERANCE TEST; INTESTINE FLORA; LIPID DIET; LIPOGENESIS; MALE; NONHUMAN; OBESITY; OXIDATIVE STRESS; POLYACRYLAMIDE GEL ELECTROPHORESIS; RAT; REAL TIME POLYMERASE CHAIN REACTION; TRIACYLGLYCEROL BLOOD LEVEL; WESTERN BLOTTING; ADIPOSE TISSUE; ADVERSE EFFECTS; ANIMAL; BACTERIUM; BLOOD; BODY COMPOSITION; COMPARATIVE STUDY; DRUG EFFECTS; FEEDING BEHAVIOR; GROWTH, DEVELOPMENT AND AGING; INFLAMMATION; KIDNEY; METABOLISM; MICROBIOLOGY; WISTAR RAT;

ADIPOSE TISSUE; ANIMALS; BACTERIA; BODY COMPOSITION; DIET, HIGH-FAT; FEEDING BEHAVIOR; FRUCTOSE; GASTROINTESTINAL MICROBIOME; GLUCOSE INTOLERANCE; INFLAMMATION; INSULIN; KIDNEY; MALE; NUTRITIVE SWEETENERS; OBESITY; OXIDATIVE STRESS; RATS, WISTAR; SUCROSE;

EID: 85018504745     PISSN: None     EISSN: 20726643     Source Type: Journal    
DOI: 10.3390/nu9040393     Document Type: Article

References (37)

1. WHO. Obesity and Overweight; WHO: Geneva, Switzerland, 2016.
2. Glendinning, J.I.; Breinager, L.; Kyrillou, E.; Lacuna, K.; Rocha, R.; Sclafani, A. Differential effects of sucrose and fructose on dietary obesity in four mouse strains. Physiol. Behav. 2010, 101, 331–343. [CrossRef] [PubMed]
3. Bagby, S.P. Obesity-initiated metabolic syndrome and the kidney: A recipe for chronic kidney disease? J. Am. Soc. Nephrol. 2004, 15, 2775–2791. [CrossRef] [PubMed]
4. Koppe, L.; Pelletier, C.C.; Alix, P.M.; Kalbacher, E.; Fouque, D.; Soulage, C.O.; Guebre-Egziabher, F. Insulin resistance in chronic kidney disease: New lessons from experimental models. Nephrol. Dial. Transpl. 2014, 29, 1666–1674. [CrossRef] [PubMed]
5. Al Khodor, S.; Shatat, I.F. Gut microbiome and kidney disease: A bidirectional relationship. Pediatr. Nephrol. 2016. [CrossRef] [PubMed]
6. Gryp, T.; Vanholder, R.; Vaneechoutte, M.; Glorieux, G. P-cresyl sulfate. Toxins 2017, 9, 52. [CrossRef] [PubMed]
7. Shirali, A.C.; Goldstein, D.R. Tracking the toll of kidney disease. J. Am. Soc. Nephrol. 2008, 19, 1444–1450. [CrossRef] [PubMed]
8. Min, H.S.; Kim, J.E.; Lee, M.H.; Song, H.K.; Lee, M.J.; Lee, J.E.; Kim, H.W.; Cha, J.J.; Hyun, Y.Y.; Han, J.Y.; et al. Effects of toll-like receptor antagonist 4,5-dihydro-3-phenyl-5-isoxasole acetic acid on the progression of kidney disease in mice on a high-fat diet. Kidney Res. Clin. Pract. 2014, 33, 33–44. [CrossRef] [PubMed]
9. Liu, J.; Zhuang, Z.J.; Bian, D.X.; Ma, X.J.; Xun, Y.H.; Yang, W.J.; Luo, Y.; Liu, Y.L.; Jia, L.; Wang, Y.; et al. Toll-like receptor-4 signalling in the progression of non-alcoholic fatty liver disease induced by high-fat and high-fructose diet in mice. Clin. Exp. Pharm. Phys. 2014, 41, 482–488. [CrossRef] [PubMed]
10. Yang, Z.H.; Miyahara, H.; Takeo, J.; Katayama, M. Diet high in fat and sucrose induces rapid onset of obesity-related metabolic syndrome partly through rapid response of genes involved in lipogenesis, insulin signalling and inflammation in mice. Diabetol. Metab. Syndr. 2012, 4, 32. [CrossRef] [PubMed]
11. Redon, J.; Lurbe, E. The kidney in obesity. Curr. Hypertens. Rep. 2015, 17, 555. [CrossRef] [PubMed]
12. Han, C.Y. Roles of reactive oxygen species on insulin resistance in adipose tissue. Diabetes Metab. J. 2016, 40, 272–279. [CrossRef] [PubMed]
13. Pedruzzi, L.M.; Stockler-Pinto, M.B.; Leite, M., Jr.; Mafra, D. Nrf2-keap1 system versus NF-kB: The good and the evil in chronic kidney disease? Biochimie 2012, 94, 2461–2466. [CrossRef] [PubMed]
14. Small, D.M.; Coombes, J.S.; Bennett, N.; Johnson, D.W.; Gobe, G.C. Oxidative stress, anti-oxidant therapies and chronic kidney disease. Nephrology 2012, 17, 311–321. [CrossRef] [PubMed]
15. Chen, S.; Zhou, S.; Wu, B.; Zhao, Y.; Liu, X.; Liang, Y.; Shao, X.; Holthofer, H.; Zou, H. Association between metabolically unhealthy overweight/obesity and chronic kidney disease: The role of inflammation. Diabetes Metab. 2014, 40, 423–430. [CrossRef] [PubMed]
16. Henriksen, E.J.; Diamond-Stanic, M.K.; Marchionne, E.M. Oxidative stress and the etiology of insulin resistance and type 2 diabetes. Free Radic. Biol. Med. 2011, 51, 993–999. [CrossRef] [PubMed]
17. Park, K.; Gross, M.; Lee, D.H.; Holvoet, P.; Himes, J.H.; Shikany, J.M.; Jacobs, D.R., Jr. Oxidative stress and insulin resistance: The coronary artery risk development in young adults study. Diabetes Care 2009, 32, 1302–1307. [CrossRef] [PubMed]
18. Stanhope, K.L. Sugar consumption, metabolic disease and obesity: The state of the controversy. Crit. Rev. Clin. Lab. Sci. 2016, 53, 52–67. [CrossRef] [PubMed]
19. Zeyda, M.; Stulnig, T.M. Obesity, inflammation, and insulin resistance—A mini-review. Gerontology 2009, 55, 379–386. [CrossRef] [PubMed]
20. Ramezani, A.; Raj, D.S. The gut microbiome, kidney disease, and targeted interventions. J. Am. Soc. Nephrol. 2014, 25, 657–670. [CrossRef] [PubMed]
21. Reeves, P.G.; Nielsen, F.H.; Fahey, G.C., Jr. AIN-93 purified diets for laboratory rodents: Final report of the american institute of nutrition ad hoc writing committee on the reformulation of the AIN-76a rodent diet. J. Nutr. 1993, 123, 1939–1951. [PubMed]
22. Avila-Nava, A.; Noriega, L.G.; Tovar, A.R.; Granados, O.; Perez-Cruz, C.; Pedraza-Chaverri, J.; Torres, N. Food combination based on a pre-hispanic mexican diet decreases metabolic and cognitive abnormalities and gut microbiota dysbiosis caused by a sucrose-enriched high-fat diet in rats. Mol. Nutr. Food Res. 2017, 61, 1501023. [CrossRef] [PubMed]
23. Ali, S.F.; LeBel, C.P.; Bondy, S.C. Reactive oxygen species formation as a biomarker of methylmercury and trimethyltin neurotoxicity. Neurotoxicology 1992, 13, 637–648. [PubMed]
24. Gerard-Monnier, D.; Erdelmeier, I.; Regnard, K.; Moze-Henry, N.; Yadan, J.C.; Chaudiere, J. Reactions of 1-methyl-2-phenylindole with malondialdehyde and 4-hydroxyalkenals. Analytical applications to a colorimetric assay of lipid peroxidation. Chem. Res. Toxicol. 1998, 11, 1176–1183. [CrossRef] [PubMed]
25. Webber, J. Energy balance in obesity. Proc. Nutr. Soc. 2003, 62, 539–543. [CrossRef] [PubMed]
26. Johnson, R.J.; Segal, M.S.; Sautin, Y.; Nakagawa, T.; Feig, D.I.; Kang, D.H.; Gersch, M.S.; Benner, S.; Sanchez- Lozada, L.G. Potential role of sugar (fructose) in the epidemicmof hypertension, obesity and the metabolic syndrome, diabetes, jidney disease, and cardiovascular disease. Am. J. Clin. Nutr. 2007, 86, 899–906. [PubMed]
27. White, J.S.; Hobbs, L. J; Fernandez, S. Fructose content and composition of commercial HFCS-sweetened carbonated beverages. Int. J. Obes. (Lond) 2015, 39, 176–182. [CrossRef] [PubMed]
28. Drozdowski, L.A.; Thomson, A.B.R. Intestinal sugar transport. World J. Gastroenterol. 2006, 12, 1657–1670. [CrossRef] [PubMed]
29. Ferolla, S.M.; Armiliato, G.N.A.; Couto, C.A.; Ferrari, T.C.A. The role of intestinal bacteria overgrowth in obesity-related non alcoholic fatty liver disease. Nutrients 2014, 6, 5583–5589. [CrossRef] [PubMed]
30. Rajilic-Stojanovic, M.; Jonkers, D.M.; Salonen, A.; Hanevik, K.; Raes, J.; Jalanka, J.; de Vos, W.M.; Manichanh, C.; Golic, N.; Enck, P.; et al. Intestinal microbiota and diet in IBS: Causes, consequences, or epiphenomena? Am. J. Gastroenterol. 2015, 110, 278–287. [CrossRef] [PubMed]
31. Barrios, C.; Beaumont, M.; Pallister, T.; Villar, J.; Goodrich, J.K.; Clark, A.; Pascual, J.; Ley, R.E.; Spector, T.D.; Bell, J.T.; et al. Gut-microbiota-metabolite axis in early renal function decline. PLoS ONE 2015, 10, e0134311. [CrossRef] [PubMed]
32. Million, M.; Maraninchi, M.; Henry, M.; Armougom, F.; Richet, H.; Carrieri, P.; Valero, R.; Raccah, D.; Vialettes, B.; Raoult, D. Obesity-associated gut microbiota is enriched in lactobacillus reuteri and depleted in bifidobacterium animalis and methanobrevibacter smithii. Int. J. Obes. (Lond) 2012, 36, 817–825. [CrossRef] [PubMed]
33. Mobini, R.; Tremaroli, V.; Stahlman, M.; Karlsson, F.; Levin, M.; Ljungberg, M.; Sohlin, M.; Berteus Forslund, H.; Perkins, R.; Backhed, F.; et al. Metabolic effects of lactobacillus reuteri dsm 17938 in people with type 2 diabetes: A randomized controlled trial. Diabetes Obes. Metab. 2017, 19, 579–589. [CrossRef] [PubMed]
34. Huang, J.Y.; Lee, S.M.; Mazmanian, S.K. The human commensal bacteroides fragilis binds intestinal mucin. Anaerobe 2011, 17, 137–141. [CrossRef] [PubMed]
35. Shoelson, S.E.; Lee, J.; Goldfine, A.B. Inflammation and insulin resistance. J. Clin. Investig. 2006, 116, 1793–1801. [CrossRef] [PubMed]
36. Mailloux, R.J.; McBride, S.L.; Harper, M.E. Unearthing the secrets of mitochondrial ros and glutathione in bioenergetics. Trends Biochem. Sci. 2013, 38, 592–602. [CrossRef] [PubMed]
37. Han, W.K.; Bailly, V.; Abichandani, R.; Thadhani, R.; Bonventre, J.V. Kidney injury molecule-1 (KIM-1): A novel biomarker for human renal proximal tubule injury. Kidney Int. 2002, 62, 237–244. [CrossRef] [PubMed]